Journal
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
Volume 26, Issue 1, Pages 17-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2016.07.010
Keywords
HPV; HPV vaccination; Anal cancer; HIV; Immunosuppression
Funding
- Merck
- Hologic
Ask authors/readers for more resources
Anal cancer is an increasingly common non AIDS-defining cancer among individuals infected with the human immunodeficiency virus (HIV). It is associated with human papillomavirus (HPV). HPV16 is the most common genotype detected in anal cancers. The HPV types detected in anal cancer are included in the 9-valent vaccine. HPV vaccines have demonstrated efficacy in reducing anal precancerous lesions in HIV-infected individuals. Standard treatment has been fluorouracil and mitomycin (or cisplatin) plus radiation. Continued studies are needed to test new treatment strategies in HIV-infected patients with anal cancer to determine which treatment protocols provide the best therapeutic index.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available